tbuckley/cabot-search huggingface dataset:
Psychological assistance and monitoring of oncological patients' quality of life
Authors: R. Manzo, F. Vitiello, M. Gilli, B. Casale, M. Hengeller, A. Tortoriello, A. Sabbatino, G. Angrisani, A. Bianco, G. Mazzarella, F. Piantedosi
Journal: Annals of Oncology (2016)
Concussion in the international ice hockey World Championships and Olympic Winter Games between 2006 and 2015
Authors: Markku Tuominen, Timo Hänninen, Jari Parkkari, Michael J Stuart, Teemu Luoto, Pekka Kannus, Mark Aubry
Journal: British Journal of Sports Medicine (2017)

Concussions in sports are a growing concern. This study describes the incidence, injury characteristics and time trends of concussions in international ice hockey.All concussions in the International Ice Hockey Federation (IIHF) World Championships (WC) and Olympic Winter Games were analysed over 9 ice hockey seasons between 2006 and 2015 using a standardised injury reporting system and diagnoses made by the team physicians.A total of 3293 games were played (169 tournaments, 1212 teams, 26 130 players) comprising 142 244 athletic game exposures. The average injury rate (IR) for concussion was 1.1 per 1000 ice hockey player-games for all IIHF WC tournaments. The IR was the highest in the men's WC A-pool tournaments and Olympic Games (IR 1.6). However, the annual IR for concussion in the men's tournaments has been lower than that in the World Junior tournaments since 2012. When a concussion occurred with contact to a flexible board, the IR was 0.2 per 1000 player games. In contrast, the IR was 1.1, if the board and glass were traditional (for the latter, RR 6.44 (95% CI 1.50 to 27.61)). In the men's tournaments, the trend of concussions caused by illegal hits decreased over the study period. After the 4th Consensus Statement on Concussion in Sport was published (2013), none of the concussed players in the men's WC returned to play on the day of injury.The annual risk of concussion in the men's WC has decreased during the study period. This was most likely due to a reduction in illegal hits. The risk of concussion was significantly lower if games were played on rinks with flexible boards and glass. Rink modifications, improved education and strict rule enforcement should be considered by policymakers in international ice hockey.
Ranolazine and prevention of trastuzumab-cardiotoxicity in experimental models.
Authors: Nicola Maurea, Carmela Coppola, Giovanna Piscopo, Domenica Rea, Carlo Maurea, Piera Maiolino, Ernesta Cavalcanti, Claudia De Lorenzo, Claudio Arra, Rosario Vincenz Iaffaioli
Journal: Journal of Clinical Oncology (2014)

e13508 Background: ErbB2 is overexpressed in about 25% of breast cancers. It modulates myocardial development and function in the heart. Trastuzumab (T), an anti-ErbB2 inhibitor, has improved the prognosis of patients with breast cancer, but is related to an increased risk of asymptomatic left ventricular (LV) dysfunction (3-34%) and heart failure (2-4%). The mechanisms of T cardiotoxicity are not entirely known and can include changes in Ca2+ regulation related to blockade of ErbB2. Here, we aim at assessing whether ranolazine (RAN), diminishing intracellular Ca2+ through its inhibition of late INa, blunts T cardiotoxicity in vivo. Methods: To evaluate cardiac function in vivo, fractional shortening (FS) and ejection fraction (EF) were measured by echocardiography M-Mode in C57BL6 mice, 2-4 mo old, pretreated with RAN (750mg/kg/day, a dose comparable to the one used in humans) per os for 3 days. RAN was then administered for additional 7 days, alone and together with T (2.25 mg/kg/day ip), according to our well established protocol. Results: In our in vivo studies, after 7 days with T, FS decreased to 49±1.5%, p<0.01 vs 60±0.5% (sham), and EF to 81+2%, p<0.01 vs 91+1% (sham). RAN alone did not change FS (59±2%) nor EF 89+1%. Interestingly, in mice treated with RAN and T, the reduction in cardiac function was milder: FS was 58±1%, EF was 90+1%, p=0.01 and p<0.01 respectively, vs T alone. Conclusions: In our mouse model, T produces LV dysfunction and RAN blunts T cardiotoxic effects. We plan to test RAN as a cardioprotective agent with other target-therapy drugs in our experimental models and to define the mechanisms of cardioprotection.
Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.
Authors: Yanyan Lou, Lixia Diao, Lauren Averett Byers, Don Lynn Gibbons, Warren Denning, Jing Wang, Vassiliki Papadimitrakopoulou, Ignacio Ivan Wistuba, Sangeeta Goswami, Maria Angelica Cortez, James Welsh, Jonathan M. Kurie, John Heymach
Journal: Journal of Clinical Oncology (2014)

3018 Background: Programmed cell death 1 (PD-1) and its ligand PD-L1 have emerged as a critical inhibitory pathway that maintains immune suppression in the tumor microenvironment. Patients with non-small-cell lung cancer (NSCLC) have responded to PD-1/PD-L1 blockade, indicating the crucial role of immune suppression in NSCLC. It is imperative to understand the immune features of NSCLC and identify biomarkers to select which patients may benefit from checkpoint blockade. Epithelial-mesenchymal transition (EMT) is a key process driving metastasis. Our previous study developed a robust EMT gene signature predicting resistance to EGFR and PI3K/Akt inhibitors, highlighting differential patterns of drug responsiveness for epithelial and mesenchymal cells. Methods: We used this EMT gene signature and gene expression profiles in adenocarcinoma from The Cancer Genome Atlas (TCGA) and the PROSPECT database at MD Anderson Cancer Center (tumors collected in 240 patients undergoing surgical resection with curative intent) to study the tumor microenvironment immune profile. Tumor samples were first classified by our validated EMT signature as epithelial (low EMT scores defined by EMT scores ≤ lowest 1/3) or mesenchymal (high EMT scores defined by EMT scores ≥ highest 1/3). Gene expression profiles of immune related genes in each tumor were then analyzed. Results: Mesenchymal NSCLC is highly associated with a distinct immune phenotype in the tumor microenvironment as compared to epithelial NSCLC. Overexpression of genes for immune inhibitory molecules including PD-L1 (P = 1.6 x 10-13), PD-1 (P = 9.5 x 10-5), CTLA-4, TIM3, BTLA, IL-10, IL-6, and TGF-b (P<0.0001 for all others) are associated with mesenchymal NSCLC in both the TCGA and PROSPECT databases. Conclusions: This study demonstrates mesenchymal NSCLC (high EMT scores) is associated with distinct immune phenotypes with increased expression of immune inhibitory molecules. This study provides a potential mechanism for EMT associated immunosuppression. It suggests EMT may be a biomarker for checkpoint inhibitors and potentially other immunotherapy agents.
482TiP Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE
Authors: T. Mok, P. Schmid, G. de Castro, K. Syrigos, C. Martin, N. Yamamoto, O. Arén, O. Arrieta, M. Gottfried, A.R. Jazieh, R. Ramlau, C. Timcheva, L. Trani
Journal: Annals of Oncology (2016)
Annals Story Slam - Colonoscopy Complication
Authors: Leo C. Katz
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - Colonoscopy ComplicationFREELeo C. Katz, MDLeo C. Katz, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0020 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Colonoscopy Complication "Colonoscopy Complication," by Leo Katz, MD (Duration 5:03)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Leo C. Katz, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, Leo.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1KeywordsColonoscopy ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Influence of KRAS status of colorectal cancer liver metastases in patients receiving neoadjuvant chemotherapy including bevacizumab prior liver resection.
Authors: S. Stremitzer, J. Maresch, T. Aschacher, B. Wolf, F. Wrba, T. Gruenberger, B. Gruenberger
Journal: Journal of Clinical Oncology (2011)

10620 Background: The prognostic value of KRAS and BRAF mutation on recurrence-free survival in patients with colorectal cancer liver metastases (CLM) receiving neoadjuvant chemotherapy including bevacizumab prior liver resection is unclear. Methods: KRAS and BRAF status of resected CLM (2005-2010) from 56 resectable patients of 3 prospective studies investigating neoadjuvant chemotherapy including bevacizumab was retrospectively assessed. Mutations were correlated to recurrence-free and overall survival. Only patients with remaining vital tumor cells in the resected specimens and those without progression were analysed (PD excluded from resection, overall < 5%). Patients received 3 neoadjuvant and 3 adjuvant cycles of oxaliplatin-containing regimens. Results:Of 56 patients, 13 showed KRAS mutation (mt), whereas BRAF mutation was not detected in a single patient. Radiological response assessment according to RECIST to neoadjuvant chemotherapy including bevacizumab revealed partial response (PR) in 49 and stable disease (SD) in 7 patients. Median Fong score of all 56 resected patients was 3 (range, 1-5). Although responses were improved compared to historicals, KRAS mt patients were less likely to have PR than patients with KRAS wild-type (wt) tumors but was not statistically significant (p=0.335). Recurrence-free survival trended to be better in KRAS wt patients (1-year 51.2%, 3-years 33.9%, 4-years 29%) compared to mt patients (1-year 38.5%, 3-years 15.4%, 4-years 15.4%), but this was also not statistically significant (log rank, p=0.093). Overall survival was significantly better in KRAS wt patients (1-year 97.4%, 3-years 88.6%, 4-years 71.8%) compared to mt (1-year 100%, 3-years 43.3%, 4-years 43.3%) (log rank, p=0.034). Conclusions: The addition of bevacizumab to oxaliplatin-based chemotherapy improved response rates irrespective of KRAS status. Primary high response to Oxaliplatin-based chemotherapy including Bevacizumab is especially desirable in mt patients as an anti-EGFR-targeted therapy cannot be alternatively offered which seems to be correlated with a prolongation of the overall survival.
Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.
Authors: Mukta Sharma, Todd A. Alonzo, April Sorrell, Robert B. Gerbing, Joanne M. Hilden, Robert J. Arceci, Gita Massey, John J. Doyle, Lisa Bayer, John P. Perentesis, Julie Ross, Franklin O. Smith, Russell Brynes, Jerry Hussong, Lois Hathaway, Alan Gamis
Journal: Blood (2006)
Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment
Authors: Roopali Saxena, Chunhua Yang, Mukkavilli Rao, Ravi Chakra Turaga, Chakravarthy Garlapati, Sushma Reddy Gundala, Kimberly Myers, Ahmed Ghareeb, Shristi Bhattarai, Golnaz Kamalinia, Sangina Bristi, Dan Su, Giovanni Gadda, Padmashree C.G. Rida, Guilherme H. Cantuaria, Ritu Aneja
Journal: Clinical Cancer Research (2017)

Purpose: Most currently available chemotherapeutic agents target rampant cell division in cancer cells, thereby affecting rapidly dividing normal cells resulting in toxic side-effects. This nonspecificity necessitates identification of novel cellular pathways that are reprogrammed selectively in cancer cells and can be exploited to develop pharmacologically superior and less toxic therapeutics. Despite growing awareness on dysregulation of lipid metabolism in cancer cells, targeting lipid biosynthesis is still largely uncharted territory. Herein, we report development of a novel nontoxic orally deliverable anticancer formulation of monoethanolamine (Etn) for prostate cancer by targeting the Kennedy pathway of phosphatidylethanolamine (PE) lipid biosynthesis.Experimental Design: We first evaluated gastrointestinal tract stability, drug-drug interaction liability, pharmacokinetic, and toxicokinetic properties of Etn to evaluate its suitability as a nontoxic orally deliverable agent. We next performed in vitro and in vivo experiments to investigate efficacy and mechanism of action.Results: Our data demonstrate that Etn exhibits excellent bioavailability, gastrointestinal tract stability, and no drug-drug interaction liability. Remarkably, orally fed Etn inhibited tumor growth in four weeks by approximately 67% in mice bearing human prostate cancer PC-3 xenografts without any apparent toxicity. Mechanistically, Etn exploits selective overexpression of choline kinase in cancer cells, resulting in accumulation of phosphoethanolamine (PhosE), accompanied by downregulation of HIF-1α that induces metabolic stress culminating into cell death.Conclusions: Our study provides first evidence for the superior anticancer activity of Etn, a simple lipid precursor formulation, whose nontoxicity conforms to FDA-approved standards, compelling its clinical development for prostate cancer management. Clin Cancer Res; 23(14); 3781-93. ©2017 AACR.
218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE)
Authors: H. Taniguchi, Y. Narita, S. Kadowaki, T. Ura, M. Ando, K. Muro, S. Hamauchi, T. Tsushima, T. Yokota, A. Todaka, N. Machida, A. Fukutomi, Y. Onozawa, H. Yasui, K. Mori, K. Yamazaki
Journal: Annals of Oncology (2016)
Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.
Authors: Francesc Bosch, Marta Crespo, Neus Villamor, Ana Muntañola, Ana Ferrer, Abel Domingo, Maria Rozman, Ciril Rozman, Armando Lopez-Guillermo, Emili Montserrat
Journal: Blood (2004)
GVHD in HLA-A2 Mismatched Transplantation Caused by a Combined CD8 Response Directed Against HLA-A2 and a CD4 Response Recognizing an HLA-A2 Derived Peptide in HLA-DR1.
Authors: Avital Amir, Menno A.W.G. van der Hoorn, Erik W.A. Marijt, Michel G.D. Kester, Roelof Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Journal: Blood (2006)
Underserved community-based walking program for breast cancer survivors.
Authors: Judy Angela Tjoe, Linda B. Piacentine, Karen M. Robinson, Alexander V. Ng, Leslie J. Waltke, Angela A. Sinner
Journal: Journal of Clinical Oncology (2016)

e288 Background: Advancements in early detection and new treatment options have improved outcomes for breast cancer survivors (BCS). With increased survivorship, improving quality of life (QOL) may be a challenge for some women. Exercise improves QOL for BCS and decreases recurrence, but, despite this many women do not routinely exercise. Underserved areas are at particular risk. Few studies have examined factors influencing exercise initiation and maintenance in underserved areas among minority overweight women. The purpose of this mixed methods study was to examine physiological outcomes and motivational factors in a community-based goal oriented walking program for BCS. Methods: A convenience sample of female BCS was recruited from an inner-city community center 12-week walking program. Women participated in physiological testing and focus groups before and after the program. Data was collected regarding strength, fitness, quality of life, and motivation of the women. Quantitative data was analyzed with paired t-tests. Two researchers independently analyzed focus groups’ transcriptions and like statements and phrases were coded. Themes emerged after discussions between the researchers. Results: The 13 participants [overweight BMI (n = 2), and obese BMI (n = 11)] had a mean survivorship of 5.4 years (range .25-14.5) years. Only 7 participants completed both pre and post physiological testing. Functional endurance significantly improved as indicated by the 6 Minute Walk Test (pre = 503(56), post = 570 (63) meters, mean(sd)), p = 0.02). While overall QOL did not improve, functional well-being showed significant improvement. Two focus group sessions were held at the beginning (n = 13) and end (n = 11) of the program. Themes emerged identifying 1) Treatment Weight Gain, 2) Familial Support, 3) Not Wanting to Go it Alone, 4) The Team Made the Difference Conclusions: Female BCS spoke of interpersonal and environmental factors involved in the decision to engage and maintain exercise with the walking program. Further research is needed to examine exercise motivation in underserved, overweight and obese breast cancer survivors.
Development and validation of a genomic signature to identify colorectal cancer patients with microsatellite instability.
Authors: Ramon Salazar, Sun Tian, Cristina Santos, Robert Rosenberg, Ulrich Nitsche, Wilma E Mesker, Sjoerd Bruin, Paul Roepman, Gabriel Capella, Iris Simon
Journal: Journal of Clinical Oncology (2012)

466 Background: Microsatellite Instability (MSI-H) occurs in 10-20% of colon tumors and has been attributed predominantly to gene silencing of DNA mismatch repairs (MMR) genes by mutation or methylation, including MSH2, PMS2 and in particular MLH1. Methods: MSI status for 276 primary stage II and III colorectal tumors have been determined (n=29 MSI-H, n=247 MSS and MSI-L) by immunohistochemically staining of MLH1 and PMS2 (for 90 patients) or by PRC amplification of six microsatellite DNA regions from paired normal and tumor tissues (for 186 patients). Full genome gene expression data for the same 276 tumors was available and used to identify genes that correlate with MSI-H status. All samples had full clinical information including 5-year follow-up and ColoPrint results (as described in Salazar et al. JCO 2011). Results: Most MSI-H patients were classified as ColoPrint low risk (26 of 29 patients; 90%) however this is only as subgroup of the 195 patients identified by ColoPrint as low risk. While ColoPrint had great prognostic power in this dataset (HR 2.37, p=0.0006), it does not identify MSI-H patients with high specificity. We therefore developed a MSI-gene signature of 64 genes using a 10-fold cross validation procedure to complement ColoPrint. The MSI-signature identifies MSI-H patients with high sensitivity (93.1% (27/29)) and high specificity (87.9% (217/247)) and an overall accuracy of 88.4% (244/276). The MSI-signature has prognostic power in the subset of stage II patients (n=215) with HR = 2.38 (95% CI 1.15-4.93, p=0.06. However, in multivariate analysis of MSI status and all clinical factors, ColoPrint was the only significant prognostic factor (HR 3.2; p=0.0014). The MSI-signature is currently validated in an independent patients set of 132 stage II patients (31 MSI-H, 101 MSS). Conclusions: The diagnostic MSI signature identifies patients with MSI-H status with high accuracy. In combination with the prognostic power of ColoPrint, the identification of MSI-H patients might add additional information for treatment of stage II patients.
High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment.
Authors: Krzysztof Giannopoulos, Michael Schmitt, Paulina Wlasiuk, Malgorzata Kowal, Monika Podhorecka, Jacek Rolinski, Anna Dmoszynska
Journal: Blood (2006)
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
Authors: E. Mini, R. D'Aurizio, G. Perrone, A. Magi, A. Lapucci, R. Tassi, C. Napoli, L. Picariello, I. Landini, M. Brugia, T. Mazzei, F. Tonelli, S. Nobili
Journal: Annals of Oncology (2016)
Everolimus post-progression on tyrosine kinase inhibitors in metastatic renal cell carcinoma: A clinical review of patients demonstrating a durable response and the effective management of treatment toxicity.
Authors: James M. Wilson, Sindhu Ramamurthy, Ian D. Pedley, Rhona McMenemin
Journal: Journal of Clinical Oncology (2012)

449 Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus has been licensed as a second line treatment in metastatic renal cell carcinoma (mRCC) following treatment failure with a tyrosine kinase inhibitor (TKI). A randomised placebo control trial of everolimus used in this setting demonstrated only a modest median progression free survival of 4.9 months (Motzer RJ, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65). Methods: We present 2 patients with a prolonged treatment response - both encountered mTOR inhibitor specific adverse events, the management of which will be discussed. Results: Patient 1: A 47 year old man with mRCC, previously treated with the Atzpodien regimen followed by sunitinib. A radiological response was seen after 2 treatment cycles of Everolimus and has remained stable for 25 months to date. A triglyceride level of 32.2 mmol/l has responded to a 50% dose reduction, dietary advice and the addition of a fibrate without loss of disease control. Patient 2: A 62 year old man with mRCC initially treated with Interferon followed by sunitinib. He developed radiological evidence of pneumonitis after 2 months of everolimus but did not experience (G3) symptoms until 2 months later. Pneumonitis responded to treatment deferral and corticosteroids and did not recur when everolimus was reintroduced. He achieved 18 months of PFS. Conclusions: Everolimus can initiate prolonged periods of progression free survival when used after progression on a TKI. The treatment is well tolerated and adverse events can be easily managed to allow ongoing therapy. Our further investigation, including tumor gene profiling, of such patients will allow a more personalised approach in the management of mRCC and improved prognostication in the clinic.
The Course of Left Ventricular Thrombus Formation following Primary Percutaneous Coronary Intervention as Assessed by Cardiac Magnetic Resonance Imaging in Acute Myocardial Infarction
Authors: Ronak Delewi, Robin Nijveldt, Anja van der Laan, Alexander Hirsch, Pieter van der Vleuten, Margriet Klees, Jan G. Tijssen, Albert C. van Rossum, Felix Zijlstra, Jan J. Piek
Journal: Circulation (2010)
Prevalence of Animal Allergy in Korean Veterinarians and Veterinary Researchers
Authors: Sang Min Lee, Jung Woo Shim, Hong Seok Park, Shin Myung Kang, Yu Jin Kim, Sun Young Kyung, Jeong-Woong Park, Sung Hwan Jeong, Sang Pyo Lee
Journal: Journal of Allergy and Clinical Immunology (2017)